Abivax S.A. (ABVX) Consolidated Net Income (2022 - 2026)

Abivax (ABVX) has reported Consolidated Net Income for 5 consecutive years, with -$56.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Consolidated Net Income fell 2.04% year-over-year to -$56.2 million; the TTM figure through Mar 2026 stood at -$372.2 million (down 86.54% YoY), while the FY2025 annual figure was -$377.7 million, down 100.62% from the prior year.
• Consolidated Net Income came in at -$56.2 million for Q1 2026 at Abivax, up from -$81.9 million in the prior quarter.
• The five-year high for Consolidated Net Income was -$41.8 million in Q2 2024, with the low at -$179.3 million in Q3 2025.
• Average Consolidated Net Income over 5 years is -$74.7 million, with a median of -$56.2 million recorded in 2026.
• Across the five-year window, Consolidated Net Income surged 69.33% in 2024 and tumbled 195.6% in 2025, its largest moves.
• Year by year, Consolidated Net Income stood at -$66.1 million in 2022, then slumped by 107.34% to -$137.1 million in 2023, then soared by 69.33% to -$42.0 million in 2024, then plunged by 94.84% to -$81.9 million in 2025, then jumped by 31.37% to -$56.2 million in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$56.2 million, -$81.9 million, and -$179.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.